Home/Filings/4/0001415889-23-004315
4//SEC Filing

ROBERTSON MICHELLE 4

Accession 0001415889-23-004315

CIK 0001650664other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 4:30 PM ET

Size

9.1 KB

Accession

0001415889-23-004315

Insider Transaction Report

Form 4
Period: 2023-03-02
ROBERTSON MICHELLE
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2023-03-02+31,500107,743 total
  • Sale

    Common Stock

    2023-03-03$8.89/sh184$1,636107,559 total
  • Award

    Stock Option (right to buy)

    2023-03-02+94,50094,500 total
    Exercise: $8.72Exp: 2033-03-01Common Stock (94,500 underlying)
Footnotes (3)
  • [F1]The common stock received by the Reporting person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
  • [F2]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
  • [F3]This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.

Issuer

Editas Medicine, Inc.

CIK 0001650664

Entity typeother

Related Parties

1
  • filerCIK 0001755098

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:30 PM ET
Size
9.1 KB